blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2532676

EP2532676 - Protease-regulated antibody [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  22.11.2019
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  17.02.2017
FormerGrant of patent is intended
Status updated on  03.02.2017
Most recent event   Tooltip06.03.2020Lapse of the patent in a contracting state
New state(s): TR		published on 08.04.2020  [2020/15]
Applicant(s)For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
[2012/50]
Inventor(s)01 / Bing, Liu
5389 Saddleback
Richmond, CA 94803 / US
02 / Light, David
614 So. Fremont St.
San Mateo, CA 94402 / US
03 / Zhuozhi, Wang
1388 Broadway, Unit 383
Millbrae, CA 94030 / US
04 / Schneider, Doug
3329 Walnut Lane
Lafayette, CA 94549 / US
 [2012/50]
Representative(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[N/P]
Former [2017/12]BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 10
40789 Monheim am Rhein / DE
Former [2013/30]BIP Patents
c/o Bayer Intellectual Property GmbH
Creative Campus Monheim
Alfred-Nobel-Straße 10
40789 Monheim / DE
Application number, filing date12172879.416.08.2008
[2012/50]
Priority number, dateUS20070955913P15.08.2007         Original published format: US 955913 P
[2012/50]
Previously filed application, dateWO2008EP0675016.08.2008
[2012/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2532676
Date:12.12.2012
Language:EN
[2012/50]
Type: B1 Patent specification 
No.:EP2532676
Date:22.03.2017
Language:EN
[2017/12]
Search report(s)(Supplementary) European search report - dispatched on:EP08.11.2012
ClassificationIPC:C07K16/00, A61K47/50, C07K16/30, C07K16/36, C07K16/46
[2017/12]
CPC:
C07K16/468 (EP,US); A61K39/3955 (US); A61K39/39558 (US);
A61K45/06 (US); A61K47/6807 (EP,US); A61K47/6809 (EP,US);
A61K47/6821 (EP,US); A61K47/6827 (EP,US); A61K47/6829 (EP,US);
A61K47/6851 (EP,US); A61K47/6869 (EP,US); A61P1/04 (EP);
A61P1/12 (EP); A61P1/16 (EP); A61P11/00 (EP);
A61P13/12 (EP); A61P17/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P25/00 (EP); A61P29/00 (EP);
A61P3/10 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P31/06 (EP); A61P31/14 (EP); A61P31/18 (EP);
A61P31/20 (EP); A61P33/06 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/02 (EP); A61P5/14 (EP);
A61P7/06 (EP); A61P9/00 (EP); C07K16/3069 (EP,US);
C07K16/3076 (EP,US); C07K16/36 (EP,US); A61K2039/505 (EP,US);
C07K2317/31 (EP,US); C07K2317/56 (EP,US); C07K2317/64 (EP,US);
Y02A50/30 (EP) (-)
Former IPC [2012/50]C07K16/00, A61K47/48, C07K16/30, C07K16/36, C07K16/46
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/12]
Former [2012/50]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Protease-regulierter Antikörper[2012/50]
English:Protease-regulated antibody[2012/50]
French:Anticorps regulé de protéase[2012/50]
Examination procedure12.06.2013Amendment by applicant (claims and/or description)
12.06.2013Examination requested  [2013/30]
09.11.2015Despatch of a communication from the examining division (Time limit: M04)
04.03.2016Reply to a communication from the examining division
18.10.2016Communication of intention to grant the patent
01.02.2017Fee for grant paid
01.02.2017Fee for publishing/printing paid
01.02.2017Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP08785592.0  / EP2178914
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20080785592) is  22.06.2010
Opposition(s)Opponent(s)01  21.12.2017    ADMISSIBLE
White, Nina Louise
Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Opponent's representative
Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
 [N/P]
Former [2018/05]
Opponent(s)01  21.12.2017    ADMISSIBLE
White, Nina Louise
Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Opponent's representative
Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
16.01.2018Invitation to proprietor to file observations on the notice of opposition
20.05.2019Cancellation of oral proceeding that was planned for 22.05.2019
22.05.2019Date of oral proceedings
09.08.2019Date of despatch of rejection of opposition
19.08.2019Legal effect of rejection of opposition [2019/52]
Fees paidRenewal fee
22.10.2012Renewal fee patent year 03
22.10.2012Renewal fee patent year 04
10.08.2012Renewal fee patent year 05
19.08.2013Renewal fee patent year 06
13.08.2014Renewal fee patent year 07
10.08.2015Renewal fee patent year 08
11.08.2016Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.08.2008
AT22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
TR22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
GB16.08.2018
IT16.08.2018
ES17.08.2018
FR31.08.2018
DE01.03.2019
[2020/15]
Former [2019/47]HU16.08.2008
AT22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
GB16.08.2018
IT16.08.2018
ES17.08.2018
FR31.08.2018
DE01.03.2019
Former [2019/46]HU16.08.2008
AT22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
IT16.08.2018
FR31.08.2018
DE01.03.2019
Former [2019/38]HU16.08.2008
AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
IT16.08.2018
FR31.08.2018
DE01.03.2019
Former [2019/35]HU16.08.2008
AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
IT16.08.2018
DE01.03.2019
Former [2019/34]HU16.08.2008
AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
IT16.08.2018
Former [2019/31]HU16.08.2008
AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/43]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
MT16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/39]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/34]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
IE16.08.2017
LU16.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/21]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
CH31.08.2017
LI31.08.2017
Former [2018/18]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/14]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/09]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2017/51]AT22.03.2017
CZ22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2017/50]AT22.03.2017
CZ22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
Former [2017/49]AT22.03.2017
CZ22.03.2017
EE22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
RO22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
Former [2017/48]CZ22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
SE22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
Former [2017/41]FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
SE22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
Documents cited:Search[A] WO2007024715  (ABBOTT LAB et al.)
 [A] WO0195942  (US GOV HEALTH & HUMAN SERV et al.)
 [A]   DENNY ET AL: "Prodrug strategies in cancer therapy", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 36, no. 7-8, 1 August 2001 (2001-08-01), pages 577 - 595, XP027556826, ISSN: 0223-5234, [retrieved on 20010801]
 [A]   WEST THOMAS ET AL: "TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 21, no. 27, 20 June 2002 (2002-06-20), pages 4257 - 4265, XP002461744, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1205193

DOI:   http://dx.doi.org/10.1038/sj.onc.1205193
 [A]   LITTLE M ET AL: "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 364 - 370, XP004215163, ISSN: 0167-5699

DOI:   http://dx.doi.org/10.1016/S0167-5699(00)01668-6
 [T]   DONALDSON JOSHUA M ET AL: "Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies", CANCER BIOLOGY AND THERAPY, LANDES BIOSCIENCE, US, vol. 8, no. 22, 1 November 2009 (2009-11-01), pages 2147 - 2152, XP009135774, ISSN: 1538-4047

DOI:   http://dx.doi.org/10.4161/cbt.8.22.9765
 [T]   ORAN ERSTER ET AL: "Site-specific targeting of antibody activitymediated by disease-associated proteases", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 161, no. 3, 17 May 2012 (2012-05-17), pages 804 - 812, XP028409044, ISSN: 0168-3659, [retrieved on 20120523], DOI: 10.1016/J.JCONREL.2012.05.035

DOI:   http://dx.doi.org/10.1016/j.jconrel.2012.05.035
by applicantUS2007041978
 WO9117271
 WO9201047
 US4634664
 US4634666
 US4745181
 WO9421823
   WONG ET AL., J. IMMUNOL., vol. 139, 1987, pages 1369 - 1374
   WONG ET AL., CLIN. IMMUNOL. IMMUNOPATHOL., vol. 58, 1991, pages 236 - 250
   LUM ET AL., EXP. HEMATOL., vol. 34, 2006, pages 1 - 6
   WOLF ET AL., DRUG DISCOV. TODAY, vol. 10, 2005, pages 1237 - 1244
   CAO ET AL., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 171 - 197
   TALAC ET AL., J. BIOL. REGUL. HOMEOST. AGENTS, vol. 14, 2000, pages 175 - 181
   LU ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 2856 - 2565
   LUM ET AL., BLOOD CELLS MOL. DIS., vol. 32, 2004, pages 82 - 87
   BUTENAS ET AL., BIOCHEMISTRY, vol. 67, 2002, pages 3 - 12
   ESMON, CHEST, vol. 124, 2003, pages 26S - 32S
   COUGHLIN, ARTERIOSCLER. THROMB. VASC. BIOL., vol. 18, 1998, pages 514 - 518
   AMOUR ET AL., FEBS LETT., vol. 435, 1998, pages 39 - 44
   MOORE ET AL., ARCH. PHYSIOL. BIOCHEM., vol. 110, 2002, pages 16 - 25
   SCAMUFFA ET AL., FASEB J., vol. 20, 2006, pages 1954 - 1963
   YAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 8525 - 8529
   VEVERIS-LOWE ET AL., SEMIN. THROMB. HEMOST., vol. 33, 2007, pages 87 - 99
   XUAN ET AL., CANCER RES., vol. 66, 2006, pages 3611 - 3619
   MIAO ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 7395 - 7401
   BELORGEY ET AL., BIOCHEM. J., vol. 313, 1996, pages 555 - 560
   CHANG, EUR. J. BIOCHEM., vol. 151, 1985, pages 217 - 224
   NAGAI ET AL., METHODS ENZYMOL., vol. 153, 1987, pages 461 - 481
   BRENNAN ET AL., FEBS LETT., vol. 347, 1994, pages 80 - 84
   LIPKIND ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 13277 - 13284
   MINOD ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 38302 - 38313
   DIAN ET AL., LIFE SCIENCES NEWS - AMERSHAM BIOSCIENCES, vol. 10, 2002, pages 1 - 5
   PHILLIPS ET AL., J. MED. CHEM., vol. 41, 1998, pages 3557 - 3562
   RIESTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 8597 - 8602
   KILLEEN ET AL., BR. J. CANCER, vol. 96, 2007, pages 262 - 268
   KOHRT ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 4752 - 4756
   LIGHT ET AL., EUR. J. BIOCHEM., vol. 262, 1999, pages 522 - 533
   SAENKO ET AL., HAEMOPHILIA, vol. 12, 2006, pages 42 - 51
   TRAIL ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337
   SEGAL ET AL., CURR. OPIN. IMMUNOL., vol. 11, 1999, pages 558 - 562
   TOMLINSON ET AL., METHODS ENZYMOL., vol. 326, 2000, pages 461 - 479
   WU ET AL., NAT BIOTECHNOL., vol. 25, 2007, pages 1290 - 1297
   LU ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 2856 - 2865
   LOFFLER ET AL., LEUKEMIA, vol. 17, 2003, pages 900 - 909
   KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86
   OESTBERG ET AL., HYBRIDOMA, vol. 2, 1983, pages 361 - 367
   MERRIFIELD, J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 2154
   ROBERGE ET AL., SCIENCE, vol. 269, 1995, pages 202 - 204
   CREIGHTON: "Proteins: Structures and Molecular Principles", 1983, WH FREEMAN AND CO.
   SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual(Second Edition,", vol. 1-3, 1989, COLD SPRING HARBOR LABORATORY PRESS
   AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1995, JOHN WILEY & SONS
   BERGER; KIMMEL: "Guide to Molecular Cloning Techniques. Methods in Enzymology", vol. 152, ACADEMIC PRESS, INC.
   F. M. AUSABEL ET AL.: "Current Protocols in Molecular Biology", 2000, CURRENT PROTOCOLS
   HARLOW ET AL.: "Monoclonal Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
   PAUL: "Fundamental Immunology", 1998, LIPPINCOTT WILLIAMS & WILKINS
   HARLOW ET AL.: "Antibodies: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY PRESS
   SJOLANDER; URBANICZKY, ANAL. CHEM., vol. 63, 1991, pages 2338 - 2345
   SZABO ET AL., CURR. OPIN. STRUCT. BIOL., vol. 5, 1995, pages 699 - 705
   KRICKA, L.J.: "Molecular Biology and Biotechnology: A Comprehensive Desk Reference", 1995, VCH PUBLISHERS, article "Chemiluminescence and Bioluminescence, Analysis by"
   AVARMEAS ET AL., SCAN. J. IMMUNOL., vol. 8, no. 7, 1978, pages 7
   BAYER ET AL., METH. ENZYMOL., vol. 62, 1979, pages 308
   CHANDLER ET AL., J. IMMUNOL. METH., vol. 53, 1982, pages 187
   EKEKE; ABUKNESHA, J. STEROID BIOCHEM., vol. 11, 1979, pages 1579
   ENGVALL; PERLMANN, J. IMMUNOL., vol. 109, 1972, pages 129
   GEOGHEGAN ET AL., IMMUNOL. COMM., vol. 7, 1978, pages 1
   WILSON; NAKANE: "Immunofluorescence and Related Techniques", 1978, ELSEVIER/NORTH HOLLAND BIOMEDICAL PRESS
   WEEKS ET AL., CLIN. CHEM., vol. 29, no. 8, 1983, pages 1474 - 1479
   "Remington's Pharmaceutical Sciences., 20th edition,", 2000, MACK PUBLISHING CO.
OppositionWO2009021754
 US95591307
 WO2009025846
 US95745307
 US5298608
 WO2007024715
 WO2004009638
 WO0191798
   METZ ET AL.: "Bispecific antibody derivatives with restricted 13 September 2012 binding functionalities that are activated by proteolytic processing", PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 25, no. 10, 1 October 2012 (2012-10-01), pages 571 - 580, XP055069821

DOI:   http://dx.doi.org/10.1093/protein/gzs064
   DIGIAMMARINO ET AL.: "Ligand association rates to the inner- October 2011 variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design", MABS, vol. 3, no. 5, September 2011 (2011-09-01), pages 487 - 494, XP009168882

DOI:   http://dx.doi.org/10.4161/mabs.3.5.16326
   WU ET AL.: "Molecular construction and optimization of July/August 2009 anti-human II-1alpha/beta dual variable domain immunoglobulin ( DVD -Ig) molecules", MABS, vol. 1, no. 4, 2009, pages 339 - 347, XP002657321
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.